Volume Alert - SAN 8.41 Banco Santander $SAN Hit a high today of 8.42 Closing the day 10:30 at 8.41 +0.11 +1.33% With a day low of 8.30 and a total volume of 4,111,468.
SAN Recent Posts: http://investorshangout.com/Banco-Santander-S...SAN-52719/
SAN Banco Santander Recent Headline News
Undervalued Global Banking Groups Too Cheap To Ignore
Sebastien Couvidat - at Seeking Alpha - Sun Nov 16, 11:33PM CST
BCS: 14.71 (+0.17), SAN: 8.40 (+0.10), C: 53.40 (+0.02), BAC: 17.12 (-0.02)
Genzyme's Lemtrada Approved by the FDA
Business Wire - Fri Nov 14, 8:00PM CST
Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has approved Lemtrada(TM) (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.
SAN: 8.40 (+0.10), SNY: 47.30 (+0.62)
Market Maker Surveillance Report. GILD, QCOM, SAN, MNKD, HST, BABA, Bullishly Biased Price Friction For Monday, November 10th 2014
M2 - Tue Nov 11, 2:31AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 4913 companies with "abnormal" market making, 2783 companies with positive Friction Factors and 2128 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. GILEAD SCIENCES, INC. (NASDAQ:GILD), Qualcomm Inc (NASDAQ:QCOM), Banco Santander SA (NYSE:SAN), Mannkind Corp (NASDAQ:MNKD), Host Hotels and Resorts Inc (NYSE:HST), (NYSE:BABA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
SAN: 8.40 (+0.10), HST: 22.63 (-0.04), GILD: 101.01 (-1.05), QCOM: 70.51 (-0.34), MNKD: 6.12 (-0.04), BABA: 114.39 (-0.71)
Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma
PR Newswire - Tue Nov 11, 12:00AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.
SAN: 8.40 (+0.10), SNY: 47.30 (+0.62), REGN: 404.75 (+9.55)
Shares of SAN Down 12.4% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Nov 10, 9:52AM CST
SmarTrend identified a Downtrend for Banco Santander (NYSE:SAN) on September 29th, 2014 at $9.47. In approximately 1 month, Banco Santander has returned 12.45% as of today's recent price of $8.29.
SAN: 8.40 (+0.10)
Promises, Promises; Markets Move on Draghi: Best of Kass
at The Street - Sun Nov 09, 4:05PM CST
In highlights from his trading diary of the past week, Doug Kass says the European Central Bank is jolting the markets and Monitise is looking more shaky.
KO: 42.85 (+0.12), SAN: 8.40 (+0.10), DVN: 63.37 (-0.81), XLP: 47.96 (+0.20), V: 250.07 (+1.23), SPY: 204.03 (-0.21), IBM: 164.49 (+0.33), FB: 74.31 (-0.57), XOM: 94.57 (-0.52), PG: 88.04 (-0.07), TWTR: 40.86 (-0.99), CVX: 115.56 (-0.76)
Providence drops suit vs. Santander over lending
By JENNIFER McDERMOTT - AP - Fri Nov 07, 12:42PM CST
PROVIDENCE, R.I. (AP) — Santander Bank has agreed to give $1.3 million in grants to support low- and moderate-income neighborhoods in Providence to resolve a lawsuit filed by the city.
SAN: 8.40 (+0.10), SANW: 3.53 (-0.13)
GE Capital closes sale of GE Money Bank
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 8:13AM CST
SAN: 8.40 (+0.10), GE: 26.60 (+0.14)
Update: Banco Santander Earnings
The Investment Doctor - at Seeking Alpha - Wed Nov 05, 9:45AM CST
SAN: 8.40 (+0.10)
Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis
Business Wire - Tue Nov 04, 5:00AM CST
Genzyme, a Sanofi company, announced today enrollment of the first patient in a multicenter Phase II clinical trial to evaluate Genzyme's investigational infusion therapy vatelizumab in patients with relapsing remitting multiple sclerosis (RRMS). The trial, called EMPIRE, is designed to assess the efficacy of vatelizumab vs. placebo in RRMS patients. The safety, tolerability and pharmacokinetics of vatelizumab will also be assessed.
SAN: 8.40 (+0.10), SNY: 47.30 (+0.62)
Santander Brasil slides continues as Banco Santander boosts stake
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 10:34AM CST
SAN: 8.40 (+0.10), BSBR: 5.44 (+0.03)
Banco Santander Brasil (BSBR) Stock Continues to Sink After Share Buyout
at The Street - Mon Nov 03, 10:03AM CST
Banco Santander Brasil (BSBR) stock continues to tumble after its parent company raised its stake in the Brazilian unit to 88.3% last Friday.
SAN: 8.40 (+0.10), BSBR: 5.44 (+0.03)
Sanofi Pasteur Announces FDA Approval of Updated Prescribing Information for Fluzone® High-Dose Vaccine for Adults 65 and Older
PR Newswire - Mon Nov 03, 7:30AM CST
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental biologics license application (sBLA) for Fluzone® High-Dose (Influenza Vaccine) to include efficacy data in the Prescribing Information. These data demonstrate that Fluzone High-Dose vaccine provided improved protection against influenza ("the flu"
compared to standard-dose Fluzone vaccine (trivalent intramuscular formulation) in adults 65 years of age and older.
SAN: 8.40 (+0.10), SNY: 47.30 (+0.62)
Conference Participation, Dividend, Upcoming Annual Meeting, Training Program, and Promotional Event - Research Reports on Santander Brasil, Goldman Sachs, Visa, Banco Santander and American Express
PR Newswire - Thu Oct 30, 7:30AM CDT
Today, Analysts Review released its research reports regarding Banco Santander Brasil SA (NYSE: BSBR), The Goldman Sachs Group Inc. (NYSE: GS), Visa Inc. (NYSE: V), Banco Santander, S.A. (NYSE: SAN) and American Express Company (NYSE: AXP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7556-100free.
SAN: 8.40 (+0.10), V: 250.07 (+1.23), GS: 190.22 (+0.24), AXP: 90.04 (-0.63), BSBR: 5.44 (+0.03)
Sanofi: Sanofi Delivers Business EPS Growth of 10.3% at CER
PR Newswire - Tue Oct 28, 7:34AM CDT
Sanofi (NYSE: SNY; EURONEXT: SAN)
SAN: 8.40 (+0.10), SNY: 47.30 (+0.62)
New International GPCR Consortium Formed with Pharma and Academia to Advance Structural Information about G-protein Coupled Receptors
PR Newswire - Tue Oct 28, 5:00AM CDT
The generation of high-resolution pictures of hundreds of medically important proteins known as G-protein coupled receptors (GPCRs) will be the goal of an ambitious new international partnership. Called the GPCR Consortium, this non-profit initiative brings together major pharmaceutical companies and leading research institutes from three continents to advance GPCR research for drug development. The human body is controlled by 826 GPCRs, which are involved in a wide variety of human physiology and are implicated in many diseases. As a drug target, GPCRs are highly valuable but mechanistically poorly understood and with limited structural information that could greatly aid in finding new drug candidates.
SAN: 8.40 (+0.10), SNY: 47.30 (+0.62)
Sanofi Q3 2014 Results - Interview with Jérôme Contamine
PR Newswire - Tue Oct 28, 2:00AM CDT
Sanofi, a global and diversified healthcare leader, reports results for the third-quarter of 2014. Jérôme Contamine, Chief Financial Officer of Sanofi, comments on results and full year guidance.
SAN: 8.40 (+0.10), SNY: 47.30 (+0.62)
SmarTrend Watching for Potential Rebound in Shares of Banco Santander After 2.58% Loss
Comtex SmarTrend(R) - Mon Oct 27, 4:08PM CDT
Banco Santander (NYSE:SAN) traded in a range yesterday that spanned from a low of $8.51 to a high of $8.72. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $8.67 on volume of 38.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SAN: 8.40 (+0.10)
Skeptical markets hit sell button on EU lenders
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 11:52AM CDT
EWI: 14.40 (+0.13), SAN: 8.40 (+0.10), EUFN: 22.71 (+0.08), ING: 14.04 (+0.12), DB: 30.07 (+0.18), BBVA: 10.76 (+0.10)
80% ECB Banks Pass Stress Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 9:55AM CDT
European banks emerged as healthier. Of 123 banks that were part of the stress test, only 24 failed to meet the minimum common equity ratio (CET1) level of 5.5%.
BCS: 14.71 (+0.17), SAN: 8.40 (+0.10), HSBC: 49.99 (-0.28), DB: 30.07 (+0.18), NBG: 2.21 (-0.01), RBS: 11.93 (+0.14), LYG: 4.83 (+0.05)
SAN Recent Posts: http://investorshangout.com/Banco-Santander-S...SAN-52719/
SAN Banco Santander Recent Headline News
Undervalued Global Banking Groups Too Cheap To Ignore
Sebastien Couvidat - at Seeking Alpha - Sun Nov 16, 11:33PM CST
BCS: 14.71 (+0.17), SAN: 8.40 (+0.10), C: 53.40 (+0.02), BAC: 17.12 (-0.02)
Genzyme's Lemtrada Approved by the FDA
Business Wire - Fri Nov 14, 8:00PM CST
Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has approved Lemtrada(TM) (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.
SAN: 8.40 (+0.10), SNY: 47.30 (+0.62)
Market Maker Surveillance Report. GILD, QCOM, SAN, MNKD, HST, BABA, Bullishly Biased Price Friction For Monday, November 10th 2014
M2 - Tue Nov 11, 2:31AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 4913 companies with "abnormal" market making, 2783 companies with positive Friction Factors and 2128 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. GILEAD SCIENCES, INC. (NASDAQ:GILD), Qualcomm Inc (NASDAQ:QCOM), Banco Santander SA (NYSE:SAN), Mannkind Corp (NASDAQ:MNKD), Host Hotels and Resorts Inc (NYSE:HST), (NYSE:BABA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
SAN: 8.40 (+0.10), HST: 22.63 (-0.04), GILD: 101.01 (-1.05), QCOM: 70.51 (-0.34), MNKD: 6.12 (-0.04), BABA: 114.39 (-0.71)
Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma
PR Newswire - Tue Nov 11, 12:00AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.
SAN: 8.40 (+0.10), SNY: 47.30 (+0.62), REGN: 404.75 (+9.55)
Shares of SAN Down 12.4% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Nov 10, 9:52AM CST
SmarTrend identified a Downtrend for Banco Santander (NYSE:SAN) on September 29th, 2014 at $9.47. In approximately 1 month, Banco Santander has returned 12.45% as of today's recent price of $8.29.
SAN: 8.40 (+0.10)
Promises, Promises; Markets Move on Draghi: Best of Kass
at The Street - Sun Nov 09, 4:05PM CST
In highlights from his trading diary of the past week, Doug Kass says the European Central Bank is jolting the markets and Monitise is looking more shaky.
KO: 42.85 (+0.12), SAN: 8.40 (+0.10), DVN: 63.37 (-0.81), XLP: 47.96 (+0.20), V: 250.07 (+1.23), SPY: 204.03 (-0.21), IBM: 164.49 (+0.33), FB: 74.31 (-0.57), XOM: 94.57 (-0.52), PG: 88.04 (-0.07), TWTR: 40.86 (-0.99), CVX: 115.56 (-0.76)
Providence drops suit vs. Santander over lending
By JENNIFER McDERMOTT - AP - Fri Nov 07, 12:42PM CST
PROVIDENCE, R.I. (AP) — Santander Bank has agreed to give $1.3 million in grants to support low- and moderate-income neighborhoods in Providence to resolve a lawsuit filed by the city.
SAN: 8.40 (+0.10), SANW: 3.53 (-0.13)
GE Capital closes sale of GE Money Bank
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 8:13AM CST
SAN: 8.40 (+0.10), GE: 26.60 (+0.14)
Update: Banco Santander Earnings
The Investment Doctor - at Seeking Alpha - Wed Nov 05, 9:45AM CST
SAN: 8.40 (+0.10)
Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis
Business Wire - Tue Nov 04, 5:00AM CST
Genzyme, a Sanofi company, announced today enrollment of the first patient in a multicenter Phase II clinical trial to evaluate Genzyme's investigational infusion therapy vatelizumab in patients with relapsing remitting multiple sclerosis (RRMS). The trial, called EMPIRE, is designed to assess the efficacy of vatelizumab vs. placebo in RRMS patients. The safety, tolerability and pharmacokinetics of vatelizumab will also be assessed.
SAN: 8.40 (+0.10), SNY: 47.30 (+0.62)
Santander Brasil slides continues as Banco Santander boosts stake
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 10:34AM CST
SAN: 8.40 (+0.10), BSBR: 5.44 (+0.03)
Banco Santander Brasil (BSBR) Stock Continues to Sink After Share Buyout
at The Street - Mon Nov 03, 10:03AM CST
Banco Santander Brasil (BSBR) stock continues to tumble after its parent company raised its stake in the Brazilian unit to 88.3% last Friday.
SAN: 8.40 (+0.10), BSBR: 5.44 (+0.03)
Sanofi Pasteur Announces FDA Approval of Updated Prescribing Information for Fluzone® High-Dose Vaccine for Adults 65 and Older
PR Newswire - Mon Nov 03, 7:30AM CST
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental biologics license application (sBLA) for Fluzone® High-Dose (Influenza Vaccine) to include efficacy data in the Prescribing Information. These data demonstrate that Fluzone High-Dose vaccine provided improved protection against influenza ("the flu"
compared to standard-dose Fluzone vaccine (trivalent intramuscular formulation) in adults 65 years of age and older. SAN: 8.40 (+0.10), SNY: 47.30 (+0.62)
Conference Participation, Dividend, Upcoming Annual Meeting, Training Program, and Promotional Event - Research Reports on Santander Brasil, Goldman Sachs, Visa, Banco Santander and American Express
PR Newswire - Thu Oct 30, 7:30AM CDT
Today, Analysts Review released its research reports regarding Banco Santander Brasil SA (NYSE: BSBR), The Goldman Sachs Group Inc. (NYSE: GS), Visa Inc. (NYSE: V), Banco Santander, S.A. (NYSE: SAN) and American Express Company (NYSE: AXP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7556-100free.
SAN: 8.40 (+0.10), V: 250.07 (+1.23), GS: 190.22 (+0.24), AXP: 90.04 (-0.63), BSBR: 5.44 (+0.03)
Sanofi: Sanofi Delivers Business EPS Growth of 10.3% at CER
PR Newswire - Tue Oct 28, 7:34AM CDT
Sanofi (NYSE: SNY; EURONEXT: SAN)
SAN: 8.40 (+0.10), SNY: 47.30 (+0.62)
New International GPCR Consortium Formed with Pharma and Academia to Advance Structural Information about G-protein Coupled Receptors
PR Newswire - Tue Oct 28, 5:00AM CDT
The generation of high-resolution pictures of hundreds of medically important proteins known as G-protein coupled receptors (GPCRs) will be the goal of an ambitious new international partnership. Called the GPCR Consortium, this non-profit initiative brings together major pharmaceutical companies and leading research institutes from three continents to advance GPCR research for drug development. The human body is controlled by 826 GPCRs, which are involved in a wide variety of human physiology and are implicated in many diseases. As a drug target, GPCRs are highly valuable but mechanistically poorly understood and with limited structural information that could greatly aid in finding new drug candidates.
SAN: 8.40 (+0.10), SNY: 47.30 (+0.62)
Sanofi Q3 2014 Results - Interview with Jérôme Contamine
PR Newswire - Tue Oct 28, 2:00AM CDT
Sanofi, a global and diversified healthcare leader, reports results for the third-quarter of 2014. Jérôme Contamine, Chief Financial Officer of Sanofi, comments on results and full year guidance.
SAN: 8.40 (+0.10), SNY: 47.30 (+0.62)
SmarTrend Watching for Potential Rebound in Shares of Banco Santander After 2.58% Loss
Comtex SmarTrend(R) - Mon Oct 27, 4:08PM CDT
Banco Santander (NYSE:SAN) traded in a range yesterday that spanned from a low of $8.51 to a high of $8.72. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $8.67 on volume of 38.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SAN: 8.40 (+0.10)
Skeptical markets hit sell button on EU lenders
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 11:52AM CDT
EWI: 14.40 (+0.13), SAN: 8.40 (+0.10), EUFN: 22.71 (+0.08), ING: 14.04 (+0.12), DB: 30.07 (+0.18), BBVA: 10.76 (+0.10)
80% ECB Banks Pass Stress Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 9:55AM CDT
European banks emerged as healthier. Of 123 banks that were part of the stress test, only 24 failed to meet the minimum common equity ratio (CET1) level of 5.5%.
BCS: 14.71 (+0.17), SAN: 8.40 (+0.10), HSBC: 49.99 (-0.28), DB: 30.07 (+0.18), NBG: 2.21 (-0.01), RBS: 11.93 (+0.14), LYG: 4.83 (+0.05)
